ARCHIVES

Talactoferrin Second-Line Therapy Increases Survival In Stage IIIB/IV

This article is from The Cancer Letter archive.

Vol. 34 No. 10 | October 28, 2011

Download PDF Visit The Full Archive

Related Articles

Cancer Panel Urges Improved Funding For Basic Science

June 16, 1995

Are Cancer Drugs Getting Better? FDA’s Richard Pazdur Says “Yes”

February 14, 2014

NIH Dedicates Louis Stokes Laboratories; Royston Retires As Kimmel Center President.

June 22, 2001

NCI brings in grantees to explain their work, promise of nanotech, to advisory board.

July 16, 2004

Funding Opportunity.

July 12, 2002

Counter-Point: George Sledge Responds To Berry’s Letter: Neoadjuvant Doesn’t Predict Adjuvant In Breast Cancer

July 11, 2014